#ESMO26: Beyond its cancer vaccine, Merck brought more than two dozen studies to ESMO as it races to offset Keytruda’s patent cliff.
endpoints.newsBeyond the cancer vaccine, how did Merck’s oncology pipeline do at ESMO?Merck showcased sac-TMT wins in endometrial cancer and NSCLC at ESMO, while facing setbacks with Keytruda in breast cancer and a patient death linked to R-DXd ILD.
0 reposts0 likes